Cleveland-Cliffs (CLF) PT Raised to $28.35 at GLJ Research; Could Rise Above $180
- Dow, S&P post worst week in months after hawkish Fed spooks investors
- Fed-fueled dollar rises as bears make for exits
- Adobe (ADBE) Edges Higher After Topping Q2 Estimates, Analysts Raise PT on 'Impressive' Performance
- Fed Statement Very Bullish for Tech Stocks, Focus on Cloud and Cyber Stocks - Wedbush
- You Fight Real Physical Inflation With Rate Hikes, Not Talk of Rate Hikes; Buy the Dip in Commodities, Gold Underpriced - Goldman Sachs
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
GLJ Research analyst Gordon Johnson raised the price target on Cleveland-Cliffs (NYSE: CLF) to $28.35 (from $22.09) while maintaining a Buy rating.
The analyst commented, "According to a new analysis we built that analyzes CLF's cash flows based on various benchmark HRC price scenarios and just a handful of static assumptions, at current spot quotes CLF is trading at <0.6x forward 2022 and 2023 EBITDA, indicating substantial upside potential when extrapolating today's prices onto a mid-cycle multiple of about 5x - this compares to the current 2023 EV/EBITDA multiple for CLF peers Nucor (NUE; NC) and Steel Dynamics (STLD; NC) of 11.5x and 8.6x, respectively. Moreover, when considering our checks suggest: (i) the market is still very clearly tight, with market participants quoted as saying buyers still cannot find a mill willing to accept a spot order, and (ii) coming US steel capacity is really not much after stripping out value-added lines and idled plans (i.e., we have accounted for <5MMt incrementally coming from BRS, Bluescope, STLD, and NUE cumulatively [Ex. 1]), we see a scenario where record high prices are sustained through 2021 into 2022. Under that backdrop, should markets extrapolate record high HRC prices and apply what could be described as a mid-cycle multiple to spot assumptions, we see a sizable revaluation higher in CLF's share price as fated. That is, even when assuming 80% of the forward curve, CLF's EBITDA could be at or near $3bn. Using 80% of the curve price and a mid-cycle EBITDA multiple of 5x, we estimate a new price target of $28.35/ share (+22% upside from yesterday's closing price), up from $22.09 prior."
Johnson adds that that CLF’s shares could see +675% upside (above $180) should the market begin to extrapolate today’s HRC prices into the future at a mid-cycle EV/EBITDA multiple of 5.0x.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Piper Sandler Upgrades Biogen (BIIB) to Overweight on Proprietary Checks, Despite Prior Concerns
- $274M in Insider Sales from Previously 2nd Most Important Person at Tesla (TSLA) Should Raise Eyebrows - GLJ Research
- Hays Plc. (HAS:LN) (HAYPF) PT Raised to GBP1.88 at Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Hot Comments, Momentum Movers, Trader Talk
Related EntitiesGordon Johnson
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!